Wholesale Distribution of Pharmaceuticals
We can provide a professional service of:
- Contract Responsible Person (RP) / Deputy RP
- Wholesale Distribution Authorisation – WDA Application
- Good Distribution Practices (GDP) Compliance
- GAP Analysis and Pre-Inspection Audits
- GDP/ RP Training
- Quality Systems – Build, maintain and the maintenance
- Risk Assessment – Development and mitigation
- Audit Planning – Delivery and Corrective Action
Flexible Training and Workshops
We can offer a wide range of courses presented by professional trainers. Our courses are filled with informative and inter-active workshop content.
Pharmacist and Pharmacies
We can help entrepreneurs gain their own pharmacy by aiding with:
- NHS Contract Application
- GPhC Registration
- Standard Operating Procedures (SOP)
- Recruitment
Is your current pharmacy business at risk? We can consult you on:
- Scoping gaps in the local pharmacy services provision?
- “SWOT” analysis, bespoke marketing plan
- Essential Services Support
- GPhC Inspection preparation
- Automation and Optimisation
- Business Development
Care Quality Commission
We can be your ‘one stop shop’ for CQC Registration and Compliance. We can help with the following:
- CQC registration
- Documentation
- Quality Management Systems
- Pre Audit Analysis
- Risk Profiling and Compliance
- Bespoke Consultancy
- Business improvement
- Training and practical implementation
Latest News
Fake online Pharmacies equal fake meds
Fake online pharmacies equal fake meds, and there are still online pharmacies who are operating illegally and suppling fake/counterfeit medications to the public for a fee.
Pilot scheme cycling and walking prescription
A new pilot scheme will award 11 local authorities’ part of a £12.7 million sum to help them offer prescriptions for walking, cycling, and wheeling. The pilots are a commitment to the governments Gear Change Plan that was introduced in 2020. The funding will...
Orphan medicines
Orphan medicines are medicinal products that are intended to treat diseases which are so uncommon that it would be difficult to secure funding for drug development under usual marketing conditions.